Case Note & Summary
The case involved an appeal against a High Court order that quashed prosecutions initiated by a Drugs Inspector under the Drugs and Cosmetics Act, 1940. The respondents, Fizikem Laboratories Pvt. Ltd. and another, were accused of manufacturing and selling Ayurvedic drugs, specifically Ozomen capsules and Ozomen forte, which contained sildenafil citrate, an allopathic drug. The Drugs Inspector had taken samples of these products and found them to contain sildenafil citrate without the necessary manufacturing license. The High Court ruled that the Drugs Inspector lacked jurisdiction to prosecute under Section 32 of the Act, asserting that only an Inspector appointed under Chapter IVA could do so for Ayurvedic drugs. The appellants contended that the prosecution was valid under Chapter IV as the drugs were misbranded and adulterated, and the respondents did not possess the required license for manufacturing sildenafil citrate. The Supreme Court analyzed the relevant provisions of the Act, including definitions of Ayurvedic drugs and the powers of Inspectors. It concluded that the prosecution could be initiated under Chapter IV for violations involving allopathic components in Ayurvedic drugs. The court set aside the High Court's order, allowing the prosecution to proceed and directing that both prosecutions under Chapters IV and IVA could be consolidated. The decision emphasized the importance of regulatory compliance in drug manufacturing and the jurisdictional authority of Inspectors. The court's ruling reinstated the prosecution against the respondents for serious violations of the Act.
Headnote
A) Drugs and Cosmetics Act - Jurisdiction of Inspectors - Competence to Prosecute - Drugs and Cosmetics Act, 1940, Sections 18, 21, 27 - The court held that the Drugs Inspector under Chapter IV could prosecute for offences involving misbranding and adulteration of drugs, including Ayurvedic drugs containing allopathic components, despite the respondents' argument that only the Inspector under Chapter IVA had such authority. The High Court's quashing of the prosecution was deemed incorrect, and the appeal was allowed. (Paras 6-8)
Issue of Consideration
Whether the Drugs Inspector appointed under Section 21 of the Drugs and Cosmetics Act had jurisdiction to prosecute for offences related to Ayurvedic drugs containing sildenafil citrate.
Final Decision
The Supreme Court allowed the appeal, set aside the High Court's order, and directed that the prosecution under Chapter IV could proceed against the respondents for violations of the Drugs and Cosmetics Act.
Law Points
- Jurisdiction of Drug Inspectors
- Prosecution under Drugs and Cosmetics Act
- Misbranding and Adulteration
- Ayurvedic and Allopathic Drug Regulations
